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http://dx.doi.org/10.1016/j.kjms.201Abstract Epidural morphine in patient-controlled analgesia regimens controls postoperative
pain well but easily induces pruritus and other epidural morphine-related side effects. With 90
pregnant American Society of Anesthesiologists physical status II females scheduled for elec-
tive cesarean delivery, the present study was designed to evaluate the efficacy and safety pro-
file of patient-controlled antipruritus (PCP) use of intravenous nalbuphine-based regimens for
attenuation of postoperative pruritus and related side effects in combination with epidural
morphine patient-controlled analgesia with regard to the quality of postoperative pain man-
agement. Patients were randomly assigned to two nalbuphine groups (5 mg/kg/hour, Group
N5 or 10 mg/kg/hour, Group N10) and bolus dose of 1.6 mg/kg for PCP or the control (normal
saline) group. Comparable visual analog scale scores for rest pain at each measured time inter-
val among the three groups demonstrated that adequate pain relief was offered; however, the
cumulative dose of nalbuphine administered to the patients in Group N10 attenuated the anal-
gesic effect of epidural morphine in moving pain at POh24 only. Fewer episodes and milder
severity of pruritus were observed in patients in Groups N5 and N10 at all postoperative time
intervals. Epidural morphine provided good postoperative pain relief but with incommodiouseclare no conflicts of interest.
of Anesthesiology, Kaohsiung Medical University Hospital, Kaohsiung City, Number 100, Tzyou First
ung City, Taiwan.
il.com (K.-I Cheng).
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Nalbuphine reduces morphine pruritus and analgesia 249side effects. In addition, intravenous nalbuphine not only attenuated the incidence of pruritus
but also decreased total morphine consumption. In conclusion, intravenous administration of
low-dose nalbuphine (5 mg/kg/hour) for PCP maintained analgesia produced by epidural
morphine and offered low pruritus incidence.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cesarean delivery is one of the most common surgical
procedures, performed at an increasingly high rate [1]. A
patient-controlled administration device to deliver anal-
gesic agents is frequently used for postoperative pain
management for patients undergoing cesarean delivery,
because opioid-based regimens are the “gold standard” of
cesarean delivery analgesia [1]. The epidural morphine
setting for patient-controlled analgesia (PCA) provides good
postoperative pain relief; however, opioid-related side ef-
fects, for example, nausea, vomiting, and pruritus,
discourage patients from attempting the use of PCA [2e5].
Reduction of epidural morphine-related side effects during
PCA use thus becomes a major issue to improve quality.
A combination of various adjuvant agents with morphine
in the PCA regimen reduces the dose of morphine and
therefore decreases the incidence and severity of
morphine-related side effects. Nalbuphine is a mixed kappa
opioid agonist and mu opioid antagonist which possesses
and restores the analgesic properties of morphine while
inhibiting the action of morphine on mu opioid receptor-
induced side effects at the same time when it is coad-
ministered with morphine [6e9]. In addition, nalbuphine is
superior to naloxone for the treatment of side effects after
epidural morphine administration [10]. It therefore appears
to be a potential candidate for combination in post-
operative pain control regimens. However, the duration of
epidural morphine-induced pruritus may extend over the
effect of single nalbuphine dosage and it is difficult for
pruritus after surgical pain has faded. Whether low-dose
nalbuphine intravenous delivery to patients provides an
antipruritic effect but without a decreased analgesic effect
has not been determined. The present study was designed
to evaluate the efficacy and safety profile of patient-
controlled antipruritus (PCP) use of nalbuphine-based reg-
imens in combination with epidural morphine PCA with
regard to the quality of postoperative pain management for
adult patients who underwent cesarean delivery.
Materials and methods
In total, 90 pregnant American Society of Anesthesiologists
physical status II females who were scheduled for elective
cesarean delivery were screened for enrollment in this
prospective, randomized, single-blind study after institu-
tional approval was obtained. Patients were excluded if
they had a history of chronic opioid use, dermatitis, itchy
skin, or fit in absolute or relative contraindication to neu-
raxial anesthesia. Eligible patients were then randomly
assigned, through a computer-generated random numberlist concealed in an opaque envelope, to the two nalbu-
phine groups or to the control group after written informed
consent was obtained.
Participants were offered 12e15 mL of 2% lidocaine with
epinephrine 5 mg/mL and fentanyl 100 mg for lumbar
epidural anesthesia. Intravenous midazolam (0.03 mg/kg)
was allowed for adjuvant medication if patients felt
anxious before baby delivery. After delivery, a loading dose
of 10 mL of epidural morphine (0.06 mg/mL) with bupiva-
caine (1 mg/mL) was administered by a PCA device and
analgesia was maintained at an infusion rate of 3 mL/hour
with a bolus dose of 1 mL and a 20-minute lockout for 36
hours according to the study protocol. In nalbuphine
groups, patients either received intravenous nalbuphine
5 mg/kg/hour (Group N5) or 10 mg/kg/hour (Group N10) by
another patient-controlled device for antipruritus with a
setting of bolus dose of 1.6 mg/kg and a 10-minute lockout
for 48 hours. In the control group (Group C, nZ 30), normal
saline was offered instead.
The primary outcome was pain (at rest and moving, such
as changing body position) assessment at 12 hours, 24
hours, 36 hours, and 48 hours (POh12, POh24, POh36, and
POh48) postoperatively using the visual analog scale (VAS)
for pain in which 0 is defined as no pain and 10 as maximum
pain. The following variables were defined as secondary
outcomes: incidence of postoperative nausea and vomiting,
and antiemetic therapy requirements; incidence of pruritus
(patients were specifically asked about the desire to
scratch); and incidence of urinary retention (defined as the
requirement of bladder recatheterization after 24 hours
postoperatively). These variables were also assessed at 12
hours, 24 hours, 36 hours, and 48 hours postoperatively
through a standardized questionnaire administered by
interview by the study team member blinded to the patient
group assignment. Data were later crosschecked with data
from nursing staff records. Intravenous naloxone (0.1 mg)
was used in the ward as a rescue for pruritus if requested.
Intravenous pethidine (0.25 mg/kg) was offered for inade-
quate resting pain relief (VAS score  6).
Statistical analyses for the study were performed using
SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA). A priori
sample size analysis determined a sample size of at least 22
patients per group to have a probability of 80% chance
suffering from pruritus in the control group and a 50%
decrease of incidence to 40% pruritus in the experimental
groups with a power of 0.8 and aZof 0.05, and the authors
selected 30 patients per group for unexpected bias.
Descriptive statistics were applied on every variable. De-
mographic and clinical data were analyzed using one-way
analysis of variance and post-hoc test with Bonferroni
corrections. A p-value <0.05 was considered statistically
significant.
Table 1 Demographic data of the study population.
Group C Group N5 Group N10
Patients, n 30 30 30
Age, ya 31 (23e39) 30 (25e38) 29 (25e38)
Body mass index 28.3 (3.5) 27.0 (4.7) 27.5 (4.0)
a Data are medium (range).
Figure 2. Scores of postoperative resting and moving pain
measured by visual analog scale (VAS). (A) In resting pain,
comparable pain scores among the three groups are shown at
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The preliminary results of the study revealed no significant
difference among the groups in terms of demographic
characteristics, which included age and body mass index
(Table 1). Three patients in Group C suffered from severe
pruritus induced by epidural morphine at POh24 even after
intravenous antihistamine was offered. Naloxone was
therefore given to these patients for the relief of general-
ized itching and they were thereby excluded from the study
at POh24. Nalbuphine intravenous intake at each time in-
terval is shown (Fig. 1). Total intake of nalbuphine in Group
C, Group N5, and Group N10 was 0 mg, 16.1  2.8 mg, and
30.0  4.4 mg, respectively. Total intake of morphine in
Group C, Group N5, and Group N10 was 3.9  0.5 mg,
3.4  0.5 mg, and 3.3  0.6 mg, respectively (Fig. 1, Group
C vs. Group N5, p Z 0.001; Group C vs. Group N10,
p < 0.001).
The study showed comparable VAS scores for both
resting pain and moving pain at POh12, POh36, and POh48
among the groups, demonstrating that adequate pain relief
was offered (Fig. 2A and B). No patient needed pethidine
administration to relieve resting or moving pain.
Both fewer episodes and milder severity of pruritus were
observed for patients in Groups N5 and N10 at allFigure 1. Intake of intravenous nalbuphine and epidural
morphine doses. Doses of intravenous nalbuphine with bolus
and infusion are presented at each time interval. There is a
significant difference in Group C compared with Groups N5 or
N10. Doses of epidural morphine are presented as total dose
intake. There was a significant difference among groups. Group
C: without nalbuphine administration; Group N5: intravenous
nalbuphine, 5 mg/kg/hour; Group N10: intravenous nalbuphine,
10 mg/kg/hour.
each time interval. (B) In moving pain, Group N10 showed high
scores compared with Group C (*pZ 0.026, one-way analysis of
variance) at POh24. Comparable pain scores obtained at the
other time intervals among the three groups. Group C: without
nalbuphine administration; Group N5: intravenous nalbuphine,
5 mg/kg/hour; Group N10: intravenous nalbuphine, 10 mg/kg/
hour.postoperative time intervals. In addition, the severity of
pruritus induced by dressing tape was significantly milder
for patients in Groups N5 and N10 at POh48 (Group C vs.
Groups N5 and N10, p Z 0.021; Table 2). Among the pa-
tients in Group C, there were 17 out of 30, 22 out of 30, 17
out of 27, and 10 out of 27 patients who suffered from
pruritus at POh12, POh24, POh36, and POh48, respectively
(Tables 2 and 3). Therefore, the overall incidence of pru-
ritus during epidural morphine PCA ranged between 37%
and 73% (morphine was offered for 36 hours
postoperatively).
Other side effects recorded for the study included
nausea (Group C Z 3/30; Group N5 Z 0/30; Group
N10Z 2/30), vomiting (Group CZ 2/30; Group N5Z 0/30;
Group N10Z 1/30), and headache (Group CZ 2/30; Group
N5 Z 0/30; Group N10 Z 1/30), which demonstrated
comparable incidences without significant differences
among the groups. No dizziness was noted for patients in
Group C regardless of whether the patients were in resting,
Table 2 Pruritus locations caused by epidural morphine
with or without intravenous nalbuphine administration.
Time Location Group p
Ca N5 N10
POh12 Face and neck 6 5 2 0.118
Limbs 4 2 7
Trunk 8 5 1
Back 5 5 2
Patients suffered 17 10 8
Did not suffer 13 20 22 0.044*
POh24 Face and neck 10 5 5 0.573
Limbs 16 2 9
Trunk 16 5 4
Back 12 5 3
Patients suffered 22 12 12 0.005**
Did not suffer 8 18 18
POh36 Face and neck 8 2 2 0.99
Limbs 11 4 5
Trunk 10 3 3
Back 9 3 2
Patients suffered 17 9 8 0.009**
Did not suffer 10 21 22
POh48 Face and neck 2 0 0 0.661
Limbs 7 0 0
Trunk 6 1 1
Back 5 1 2
Patients suffered 10 2 1 0.001**
Did not suffer 17 28 29
Dressing tape on back
Pruritus
Yes 16 7 9 0.021*
No 11 23 21
*p < 0.05.
**p < 0.01.
a Thirty patients collected in Group C in POh12 and POh24
time intervals and 27 patients collected in POh36 and POh48
time intervals.
Table 3 Intravenous nalbuphine attenuates the incidence
and severity of pruritus induced by epidural morphine.
Time Grade Group p
C N5 N10
POh12 None 13 18 22 0.043*
Mild 16 12 8
Moderate 1 0 0
Severe 0 0 0
POh24 None 8 15 17 0.016*
Mild 16 15 13
Moderate 3 0 0
Severea 3 0 0
POh36 None 10 21 21 0.036*
Mild 14 8 9
Moderate 3 1 0
Severe 0 0 0
POh48 None 16 28 29 <0.001***
Mild 11 2 1
Moderate 0 0 0
Severe 0 0 0
*p < 0.05.
***p < 0.001.
a Three patients in Group C were categorized to severe grade
because pruritus needed naloxone infusion.
Nalbuphine reduces morphine pruritus and analgesia 251sitting, or standing positions. However, three patients in
Group N10 showed mild dizziness at POh12 (p Z 0.035,
Group N10 vs. Groups C and N5), and symptoms then sub-
sided without further treatment. No patient complained of
backache during the study.Discussion
In the present study, epidural morphine PCA provided
adequate postoperative pain control in post-cesarean de-
livery patients but with up to 22 out of 30 (73%) patients
suffering from pruritus. Epidural morphine combined with
low-dose intravenous nalbuphine for PCP still provided
adequate postoperative pain control. However, reversal of
analgesic effect of epidural morphine was found in patients
in Group N10 for presentation of high VAS score in both
categories of resting or moving pain.
Epidural morphine for postoperative pain control was
associated with side effects of nausea and vomiting, pru-
ritus, urinary retention, and gastrointestinal ileus [11e13].
The incidence of pruritus for parturients after cesareandelivery using spinal morphine was >70% [4,8,14,15]. The
high overall incidence of itching discouraged patients from
the use of epidural morphine [2,3], because surgical
manipulation may contribute to gastrointestinal ileus and
urinary retention [3], and fluid management may influence
the incidence of nausea and vomiting [13]. Accordingly, the
authors focused on pruritus attenuation for nalbuphine PCP
use and attempted to improve both the quality and
acceptance of postoperative analgesia after cesarean de-
livery. Although the analgesic duration was not correlated
with the dosage in a range of 2e5 mg of epidural morphine
[16], the more intraspinal morphine administered the
higher the pruritus incidence [17]. Nalbuphine has been
demonstrated to decrease neuraxial morphine-induced
pruritus either via bolus or infusion administration
[8,16,18]. However, proper dosage for intravenous nalbu-
phine for patients to receive epidural morphine for good
analgesia without the side effect of pruritus is not yet
determined. A combination of intravenous low-dose nal-
buphine (10 mg/mL) and morphine (1 mg/mL) showed no
effect in decreasing pruritus incidence [19]. Penning et al.
[20] demonstrated that 0.1 mg/kg of intravenous nalbu-
phine was needed to antagonize pruritus for patients who
received 0.1 mg/kg of epidural morphine for analgesia for
elective total abdominal hysterectomy [20]. However,
another study revealed that intravenous infusion of nalbu-
phine at 60 mg/kg/hour decreased pruritus in total hyster-
ectomy patients receiving an epidural of 3 mg of morphine
for postoperative pain management [7]. In the present
study, intravenous low dose of nalbuphine (5 mg/kg/hour)
was demonstrated to decrease the incidence and severity
of pruritus caused by epidural morphine. We believe that
this is attributed to the significantly reduced morphine
doses used in the study groups. In other words, intravenous
252 M.-K. Chen et al.nalbuphine tapers the dose of epidural morphine. Similar
results were evidenced by Yeh et al. [21], demonstrating
that optimal combination of morphine and nalbuphine in
PCA decreases the incidence of pruritus in a ratio-
dependent manner. Whether other ultra-low doses of nal-
buphine show similar effects to attenuate side effects is not
realized. Further investigation should be carried out to
elucidate the optimal nalbuphine dose for epidural
morphine-induced pruritus.
Different drugs are used to prevent or to treat post-
operative pruritus, which include antihistamines (e.g.,
diphenhydramine, promethazine), 5-HT3 (serotonin) re-
ceptor antagonists (e.g., ondansetron, droperidol), opioid
antagonists (e.g., naloxone, nalmefene), opioid agonist
antagonists (e.g., nalbuphine), and nonsteroidal anti-
inflammatory drugs [22e24]. Morphine is believed to lead
to histamine release and increase serum histamine [25].
However, when neuraxial morphine is used, pruritus does
not seem to be attributed to histamine release solely. An-
tihistamines such as promethazine have been reported to
be effective for pruritus [26]; nevertheless, antihistamines
for prevention of epidural morphine-induced pruritus are
still contradictory as well as/unlike serotonin receptor an-
tagonists [8,27,28]. In surgical patients, various doses of
naloxone were used mainly for the reversal of epidural
morphine-induced respiratory depression; in addition, a
tendency for dose-related decreases in pruritus and nausea
was noted. However, higher naloxone dose adversely
affected analgesia [10,25,29]. In the current study, the
authors found no change in analgesia after a low dose of
nalbuphine (Group N5) was offered, whereas moving pain
scores increased significantly at POh24 after a high dose of
nalbuphine (Group N10) was offered. In addition, the
severity of pruritus induced by dressing tape was signifi-
cantly milder for patients in Groups N5 and N10 at POh48,
indicating that nalbuphine attenuates itching of different
origins. Our finding that nalbuphine decreased both inci-
dence and severity of pruritus during the entire 48-hour
study period appears to contradict many previous studies
in demonstrating an effect.
Our study had some limitations. First, intravenous nal-
buphine of 5 mg/kg/hour was defined as “low dose” in the
study. A lower dose of nalbuphine to demonstrate similar
antipruritus effects without compromising analgesia war-
rants further study at a larger scale. Second, two patient-
controlled devices were needed in the study, which indi-
cated a higher workload for nursing staff. However, tags on
lines and devices were able to clearly register each line
function and prevent improper treatment in the present
study. Third, the study was designed for the reduction of
opioid-related side effects during epidural morphine PCA. A
large, prospective randomized study is warranted to
determine whether the study results can be extrapolated to
other neuraxial anesthesia.
In conclusion, epidural morphine PCA provides good
postoperative pain relief but with incommodious side ef-
fects for patients undergoing cesarean delivery. In the
present study, intravenous low-dose nalbuphine (5 mg/kg/
hour) for PCP maintained analgesia produced by epidural
morphine and offered low pruritus incidence. Low-dose
nalbuphine with intraspinal morphine should be recom-
mended in patients undergoing cesarean delivery becauseit is efficacious to attenuate morphine-induced pruritus
without compromising postoperative analgesic effects.
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